Sales of shingles vaccines have increased following recent research studies linking immunization to a lower risk of developing dementia. Adults aged 50 and older face decisions regarding the shots, while researchers continue investigating the biological mechanisms behind the association across international health datasets.
Research Links Shingrix and Older Vaccines to Lower Dementia Risk
A large study published in the Annals of Internal Medicine found that older adults who received the shingles vaccine had a 24 percent lower risk of developing Alzheimer’s disease or other forms of dementia compared to unvaccinated peers. Researchers at Brown University and other institutions reviewed electronic health records and Medicare claims for 509,926 older Americans admitted to skilled nursing facilities between 2017 and 2022. The mean age of the participants was approximately 79, and none carried a dementia diagnosis upon admission.
Over a four-year follow-up period, dementia developed in 18.8 percent of individuals who received at least one dose of the shingles vaccine. In contrast, 24.6 percent of unvaccinated participants developed the condition. That translates to a 24 relative reduction in risk, with researchers estimating the intervention could potentially prevent one in every 17 dementia cases.
Natural Experiments and International Data Validate the Association
Pascal Geldsetzer, assistant professor of medicine in primary care and population health at Stanford, studies natural experiments in electronic health record data to examine the phenomenon. Age-based eligibility rules for vaccination create comparable groups where birth dates near a cutoff determine who receives the shot. Using natural experiments, Geldsetzer’s team found that shingles vaccination is associated with a substantial reduction in dementia risk across several countries.
In one analysis, researchers estimated that vaccination reduced dementia risk over a seven-year span by about 20 percent. Similar patterns emerge across different datasets, health systems, mild cognitive impairment assessments, and outcomes among patients already diagnosed with dementia. We see benefits also among those who already have dementia,
Geldsetzer noted in a Stanford Department of Medicine interview. We see reductions in your probability of dying from dementia.
We estimate that shingles vaccination reduces your risk of dementia over 7 years by 20%.
Dr. Pascal Geldsetzer, Assistant Professor of Medicine in Primary Care and Population Health at Stanford, via Stanford
Scientific Theories on How Virus Reactivation Affects the Brain
Scientists continue exploring why a vaccine designed to prevent painful skin eruptions might influence cognitive health. The varicella zoster virus, which causes chickenpox and remains dormant in the nervous system before reactivating as shingles, has been linked to increased risks of heart disease and stroke. Some research indicates the virus may damage blood vessel linings, including cerebral vessels, or directly harm nerve cells.
Infections can also elevate brain inflammation, which contributes to the onset of dementia. By limiting virus reactivation and infection severity, vaccines may suppress inflammatory pathways. The shingles vaccine is recommended for adults 50 and older and is administered in two doses spaced two to six months apart. The study published in July 2026 examined the newer recombinant vaccine, Shingrix, building on earlier investigations that evaluated older live-attenuated formulations.
Public Demand and Private Costs Shape Vaccination Access
As findings circulate, public interest has translated into tangible shifts in immunization demand. Sales of shingles jabs have risen as individuals seek out the vaccine specifically for potential cognitive protection. However, health systems and pricing structures create financial hurdles for people who lack public coverage eligibility.
In the United Kingdom, a full course of two doses can cost around £450 privately for individuals who do not qualify for free NHS administration. Out-of-pocket expenses prompt questions regarding equitable access for older adults hoping to mitigate neurological risks independently.
Unresolved Questions in Observational and Causal Research
Despite consistent associations across multiple epidemiological datasets, researchers emphasize that observational studies show correlation rather than definitive causation. Individuals who proactively receive vaccines often maintain different health behaviors and socioeconomic advantages that influence brain health independently.
Investigators note that it is not yet clear whether the relationship is causal or what exact biological mechanisms account for the protective signal. Future evaluations will determine whether newer recombinant formulations replicate the long-term outcomes observed with older vaccines across diverse patient populations.